Loading
A phase 3 trial of Trastuzumab brengitecan, Trastuzumab emtansine in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer is a phase 3 interventional study registered as NCT06316531 by Sichuan Baili Pharmaceutical Co., Ltd., with 274 participants enrolled, started 2024-05-08 and due to reach its primary completion in 2026-10. Interventions recorded: BL-M07D1, T-DM1. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Shares Trastuzumab brengitecan, Trastuzumab emtansine, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).